Early detection of gastric cancer: a novel circulating microbiome DNA based liquid biopsy assay.
A blood test using AI could help detect stomach cancer earlier and more accurately, potentially catching more cases at treatable early stages.
A machine learning model trained on plasma circulating microbiome DNA signatures achieved AUC 0.914 for gastric cancer detection in an independent multicenter validation cohort of 299 participants. The model demonstrated strong performance in early-stage (Stage I) detection with AUC 0.792, with a stage-shift effect suggesting potential for earlier diagnoses in practice.
What the study was
- Study design
- Prospective diagnostic validation study with training/testing and independent multicenter cohort
- Population
- Patients with gastric cancer (all stages) and controls; multicenter China
- Sample size
- 885
- Category
- Early Detection
- Maturity
- Validated
- Journal
- NPJ precision oncology
Why it surfaced
Novel circulating microbiome DNA approach to gastric cancer early detection; multicenter independent validation with AUC 0.914 and specific Stage I performance data. Gastric cancer carries high global burden and limited early detection tools. Novelty high (microbiome DNA vs ctDNA). Further prospective validation required before clinical deployment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.